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Elevated HbA1c is not associated 
with recurrent venous 
thromboembolism in the elderly, 
but with all-cause mortality– the 
SWEETCO 65+ study
Alexandra Mathis1, Lukas Villiger1, Martin F. Reiner2,3, Michael Egloff2, Hans Ruedi Schmid4, 
Simona Stivala  3, Andreas Limacher5, Marie Mean6,7, Drahomir Aujesky6, Nicolas Rodondi6,8, 
Anna Angelillo-Scherrer9,10, Marc Righini11, Daniel Staub12, Markus Aschwanden12, 
Beat Frauchiger13, Joseph Osterwalder14, Nils Kucher15, Christian M. Matter3,16, 
Martin Banyai17, Oliver Hugli  18 & Juerg H. Beer2,3*
The association of glycated hemoglobin (HbA1c) with venous thromboembolism (VTE) and death in 
the elderly is unknown. In the SWEETCO 65+ study we analyzed prospectively a Swiss Cohort of Elderly 
Patients with Venous Thromboembolism (SWITCO 65+). 888 patients were enrolled for the SWEETCO 
65+ analysis. HbA1c was determined at baseline and divided into three categories (HbA1c < 5.7%, 
normal range; 5.7–6.49%, pre-diabetic range; and >6.5%, diabetic range). Median follow-up was 2.5 
years. The primary endpoint was recurrent VTE. Secondary endpoints included all-cause mortality 
and major bleeds. The total prevalence of diabetes was 22.1%. The risk of recurrent VTE was similar 
in patients with HbA1c with pre-diabetes (adjusted subhazard ratio (aSHR) 1.07 [0.70 to 1.63]) and 
diabetes (aSHR 0.73 [0.39 to 1.37]) as compared to those with a HbA1c in the normal range. However, 
a HbA1c ≥ 6.5% (median IQ range 7.0 [6.70;7.60]) was significantly associated with a higher risk of all-
cause mortality (adjusted hazard ratio [aHR] 1.83 [1.21 to 2.75]). In summary we found no association 
between HbA1c and major bleeding. Elevated HbA1c levels are not associated with recurrent VTE but 
with increased all-cause mortality in an elderly population with acute VTE.
Venous thromboembolism (VTE) is a major cause of cardiovascular mortality1. Recurrence of VTE occurs in 
29% of patients within 5 years after suspending anticoagulant treatment2, and life-long anticoagulation is rec-
ommended in unprovoked or recurrent VTE after taking the bleeding risk into consideration3. Anticoagulation 
is associated with serious side effects, particularly major bleeding, and increased health-care costs4,5. Therefore, 
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efforts are required to identify and reduce risk factors for recurrent VTE in order to optimize treatment strategies 
for patients with VTE.
Patients with VTE are at increased risk of stroke and myocardial infarction6–8; hence, shared risk factors for 
arterial and venous thrombogenesis are currently discussed including diabetes mellitus (DM), hypertension, 
tobacco use, obesity, and dyslipidemia9–11. All provoke inflammation, hypercoagulability and endothelial injury, 
finally causing arterial and venous thromboembolism12–28. Experimental studies have shown higher platelet (re)
activity16,29–31 and increased levels of clotting factors including fibrinogen, factor V, VII, VIII, X, XI, XII, as well 
as kallikrein and von Willebrand factor in patients with hyperglycemia18,32–34. This prothrombotic condition in 
combination with hypofibrinolysis18,32–35 observed in diabetic patients leads to a hemostatic imbalance, which 
might contribute to a higher risk for VTE and recurrent VTE. However, the association of DM and VTE in epi-
demiological studies is controversial. A meta-analysis showed an increased risk for VTE in patients with a history 
of DM36 whereas another meta-analysis found no association between DM and VTE37,38, concluding that the 
increased risk for VTE associated with DM mainly results from confounders rather than from intrinsic effects of 
DM on venous thrombotic risk38.
Studies which investigated the association between DM and recurrent VTE are scarce. One study found a sig-
nificant association and another found a positive relationship between diagnosis of DM and recurrent VTE39,40. 
Importantly, DM was mostly defined by medical chart review, self-reported DM, elevated non-fasting or fast-
ing glucose levels or seldom with an oral glucose tolerance test. In none of these studies glycated hemoglobin 
(HbA1c) was measured.
Glycated hemoglobin (HbA1c) reflects the average blood glucose levels over the last 2 to 3 months41–43. 
Large clinical trials indicate a reduction in microvascular and to a lesser extent in macrovascular complica-
tions if HbA1c values <7% in combination with treatment of other cardiovascular risk factors are achieved44–46. 
Therefore, DM as characterized by HbA1c levels might be a valid marker for predicting recurrent VTE risk.
In the current study, we investigated the association of HbA1c levels with recurrent VTE, all-cause mortal-
ity, and major bleedings in patients aged ≥65 years with acute VTE. We hypothesized that recurrent VTE and 
all-cause mortality would be increased in patients with HbA1c ≥ 6.5%.
Methods
Study population. The SWEETCO 65+ study was performed as part of the Swiss Cohort of Elderly Patients 
with Venous Thromboembolism (SWITCO 65+), a prospective multicenter cohort study to explore the associ-
ations of clinical and biological factors as well as processes of care with short- and long-term medical outcomes 
and quality of life in elderly patients with acute VTE47. The central ethics committee in Bern and the ethics com-
mittee of northeastern Switzerland approved the study. All research was performed in accordance with relevant 
guidelines. All study participants provided signed informed consent. From September 2009 to March 2012 1,863 
in- and outpatients aged ≥65 years with objectively diagnosed, symptomatic acute VTE (deep vein thrombosis 
and/or pulmonary embolism) from all five Swiss university hospitals and four high-volume non-university teach-
ing hospitals were screened.
DVT was defined by clinical assessment and by objective confirmation by duplex flow pattern, computed 
tomography or magnetic resonance imaging venography47. Symptomatic PE was defined as a positive spiral com-
puted tomography or pulmonary angiography, a high-probability ventilation-perfusion scan, or proximal DVT 
in patients with acute chest pain, new or worsening dyspnea, hemoptysis or syncope47.
A total of 1863 patients were screened. After removal of 860 patients (398 patients refused consent; 462 
patients had at least one of the following exclusion criteria: inability to provide informed consent, follow-up 
not possible, insufficient ability to speak German or French, thrombosis at different site than lower limb or 
catheter-related thrombosis), 1,003 patients were enrolled in the SWITCO 65+ study. An additional 115 patients 
were excluded from analysis (denying use of data [n = 8], early withdrawal [n = 4], no biosample taken [n = 89], 
missing HbA1c result [n = 14]), leaving a final study sample of 888 patients for the current analysis (Supplemental 
Fig. 1).
Data collection. Trained study nurses prospectively collected baseline demographic information (age and 
gender), comorbidities (cancer, DM, BMI, chronic renal and liver disease, recent myocardial infarction and his-
tory of stroke and bleeding, recent immobilization), laboratory findings (hemoglobin, creatinine and platelets), 
VTE-related treatment before and after the index event (low-molecular-weight heparin, unfractionated heparin, 
fondaparinux, danaparoid) and concomitant antiplatelet therapy using standardized data collection forms for all 
enrolled patients. Known diabetes was defined by patient reports in addition to medical records.
Determination of HbA1c levels. HbA1c was determined at baseline using the Tina-quant Hemoglobin 
A1c III test from Roche/Hitachi, a turbidimetric inhibition immunoassay (TINIA) for the in vitro determina-
tion of hemoglobin A1c in whole blood according to the instructions of the manufacturer. Results are expressed 
as % HbA1c according to the Diabetes Control and Complications Trial assay (DCCT) and to the National 
Glycohemoglobin Standardization Program (NGSP)48. Treating physicians were unaware of the HbA1c levels.
HbA1c-categories. HbA1c was divided into three categories (HbA1c < 5.7%, normal range; HbA1c 5.7–
6.49%, pre-diabetes range; and HbA1c > 6.5%, diabetes range) according to current guidelines for the definition 
of prediabetes by HbA1c of 5.7–6.49% and diabetes by HbA1c ≥ 6.5%49–51. Achieving HbA1c values <6.5% with 
pre-existing diabetes is possible, nevertheless, in the same patients increased HbA1c may have existed before 
resulting in an elevated cardiovascular risk. Otherwise HbA1c values ≥6.5% may reflect undiagnosed DM. 
Therefore, in a second analysis, we stratified patients into two subgroups with known diabetes and no history of 
diabetes. Patients were grouped into the same HbA1c-categories as described above. As an HbA1c level of <5.7% 
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is unusual for diabetic patients and might indicate aggressively treated disease with frequent hypoglycemias, we 
took the HbA1c category pre-diabetes range as reference group for this second analysis of patients with known 
diabetes.
Endpoints. We evaluated outcomes using patient or proxy interviews, interview of the patient’s primary care 
physician, and/or hospital chart review. A committee of three blinded clinical experts determined all outcomes 
and classifies the cause of all deaths as definitely due to PE, possibly due to PE, due to major bleeding, or due to 
another cause52,53. Final classifications were made on the basis of the full consensus of this committee.
Our primary endpoint was recurrent VTE. New fatal or new non-fatal PE, or new DVT (proximal and/or 
distal) were considered as recurrent VTE. The following criteria counted for the diagnosis of recurrent VTE 
during follow-up: Abnormal results on ultrasonography for DVT and for PE, new intraluminal defects on CT or 
angiography or ventilation-perfusion lung scan showing a high-probability pattern with new perfusion defects. 
A new proximal DVT in combination with new PE symptom(s) (syncope, chest pain, shortness of breath) was 
defined as recurrent PE47.
Our secondary endpoints included mortality and major bleeding. Major bleeding was defined as symptomatic 
bleeding in a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial or 
intramuscular with compartment syndrome), bleeding with a reduction of haemoglobin ≥20 g/L, or bleeding 
leading to the transfusion ≥2 units of packed red blood cells47.
Statistical analyses. We compared baseline characteristics across HbA1c groups using the chi-squared test 
and the non-parametric Wilcoxon rank-sum test or Kruskal-Wallis rank test as appropriate. We estimated and 
compared the cumulative incidence of VTE recurrence, death, and major bleeding by HbA1c group using the 
Kaplan-Meier method and the log-rank test.
Associations between HbA1c groups and the time to a first VTE recurrence and major bleeding were assessed 
by competing risk regression, accounting for non-PE-related and non-bleeding-related death, respectively, as a 
competing event, according to the method of Fine and Gray54. The method yields subhazard ratios (SHR) with 
corresponding 95%CIs and P values for the failure event of primary interest. For all-cause mortality, an ordi-
nary Cox-regression with robust standard errors was calculated. Patients were censored when they were lost to 
follow-up (n = 3), withdrew their consent (n = 57), or completed the study without experiencing the event of 
interest or the competing event, if applicable.
Similar to our previous publication55 risk factors that had formerly been shown to be associated with VTE 
recurrence, all-cause mortality and bleeding were used to adjust the models. VTE recurrence was adjusted for 
prior VTE, provoked VTE, gender, age, active cancer, periods of anticoagulation as a time-varying covariate and 
BMI. Death was adjusted for age, gender, heart failure, immobilization, active cancer, chronic lung disease, low 
blood pressure, anemia, overt PE, history of major bleeding, high pulse, high creatinine, BMI and periods of 
anticoagulation as a time-varying covariate. Major bleeding was adjusted for age, active cancer, overt PE, anemia, 
history of major bleeding, high creatinine, antiplatelet therapy and periods of anticoagulation as a time-varying 
covariate.
Minimal adjustment was done in patients with a history of DM due to low event numbers. Similar to our pre-
vious study55 age, active cancer, and periods of anticoagulation as a time-varying covariate was used for adjust for 
recurrent VTE. Death was adjusted for active cancer, age, chronic lung disease, BMI, heart failure and periods of 
anticoagulation as a time-varying covariate. For major bleeding was adjusted for antiplatelet therapy, periods of 
anticoagulation as a time-varying covariate age and history of major bleeding.
Similar to our previous publication55 missing values in covariates used for adjustment were rare (<8%) and 
thus assumed to be normal or absent. All analyses were done using Stata 14 (Stata Corporation, College Station, 
Texas).
Ethics approval and consent to participate. The central ethics committee in Bern and the ethics com-
mittee of northeastern Switzerland approved the study. All research was performed in accordance with relevant 
guidelines. All study participants provided signed informed consent; the full description of the study design has 
been registered on clinical trials.gov identifier NCT00973596.
Consent for publication. The journal Primary and Hospital Care has approved the use of the previous 
published data and figures.
Results
Study population. The mean age of patients was 75 years and 46% were female. Patients’ baseline charac-
teristics were comparable across HbA1c categories with the following exceptions (Table 1): BMI differed signif-
icantly between the HbA1c categories. Patients with a normal HbA1c had a significantly higher prevalence of 
provoked index VTE, major surgery and immobilization during the last 3 months compared to other categories. 
Patients with HbA1c in diabetes range had significantly higher prevalence of arterial hypertension, chronic renal 
disease and concomitant antiplatelet therapy and those with HbA1c in pre-diabetes range had less often a history 
of major bleeding and anemia compared with the other categories.
Prevalence of diabetes and prediabetes. A history of diabetes was identified in 15.6% (n = 139) of the 
study population. After HbA1c determination, the prevalence of diabetes increased to 22.1% (n = 196). Only 
6.1% (n = 54) of the study population had an HbA1c > 7.3% and HbA1c > 8% was seen in 2.9% only (n = 26). 
The prevalence of prediabetes in patients with no history of diabetes was high, namely 36.0% (n = 266) and 30% 
in the whole study population.
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Recurrent VTE. Patients were followed for up to four years (median 2.5 years). After 3 years, the cumulative 
incidence of the recurrent VTE did not differ between groups (Fig. 1). During the whole follow-up, the risk for 
recurrent VTE in patients with HbA1c in pre-diabetes range (adjusted subhazard ratio [aSHR] 1.07 [0.70–1.63], 
p = 0.756) and diabetes range (aSHR 0.73 [0.39–1.37], p = 0.328) was comparable to patients with normal range 
HbA1c (Table 2). Likewise, in a subgroup analysis of patients with and without history of diabetes, the risk for 
recurrent VTE did not differ between HbA1c-categories (Table 2).
All-cause mortality. Patients with HbA1c in diabetes range had a significantly higher mortality risk com-
pared to patients with HbA1c in normal range (aHR 1.83 [1.21–2.75], p = 0.004), whereas we did not observe a 
higher risk for mortality in patients with HbA1c in pre-diabetes range (aHR 1.17 [0.82–1.69], p = 0.388) (Fig. 2 
All
Category
normal range
HbA1c <5.7%
Category
pre-diabetes range
HbA1c 5.7 to 6.49%
Category
diabetes range
HbA1c ≥6.5%
p-value
n (%) or
median (IQ-range)
n (%) or
median (IQ-range)
n (%) or
median (IQ-range)
n (%) or
median (IQ-range)
Total N N = 888 N = 452 N = 300 N = 136
Age 75.00 (69.00; 81.00) 74.00 (69.00; 80.75) 76.00 (70.00; 82.00) 75.00 (69.00; 81.00) 0.079
Female gender 408 (46%) 214 (47%) 137 (46%) 57 (42%) 0.533
BMI 26.60 (24.10; 29.80) 26.00 (23.65; 29.10) 27.00 (24.20; 30.10) 28.10 (24.80; 31.10) <0.001
Overt PE 619 (70%) 309 (68%) 210 (70%) 100 (74%) 0.512
Prior VTE 254 (29%) 126 (28%) 86 (29%) 42 (31%) 0.793
Provoked index VTE 258 (29%) 159 (35%) 65 (22%) 34 (25%) <0.001
Major surgery during the last 3 months 131 (15%) 94 (21%) 25 (8%) 12 (9%) <0.001
Current oestrogen therapy during the last 3 months 27 (3%) 15 (3%) 7 (2%) 5 (4%) 0.661
Immobilization during the last 3 months 191 (22%) 116 (26%) 50 (17%) 25 (18%) 0.008
Active cancer 160 (18%) 90 (20%) 47 (16%) 23 (17%) 0.312
Known diabetes (as reported) 139 (16%) 26 (6%) 34 (11%) 79 (58%) <0.001
History of major bleeding 89 (10%) 60 (13%) 16 (5%) 13 (10%) 0.002
Arterial hypertension 571 (64%) 270 (60%) 196 (65%) 105 (77%) 0.001
Chronic or acute heart failure 105 (12%) 47 (10%) 34 (11%) 24 (18%) 0.068
Cerebrovascular disease (stroke, TIA) 84 (9%) 40 (9%) 30 (10%) 14 (10%) 0.815
Chronic lung disease 124 (14%) 56 (12%) 41 (14%) 27 (20%) 0.087
Chronic renal disease 163 (18%) 73 (16%) 53 (18%) 37 (27%) 0.013
Anemia 346 (39%) 196 (43%) 94 (31%) 56 (41%) 0.002
Platelet count <150 G/l 131 (15%) 71 (16%) 42 (14%) 18 (13%) 0.625
Creatinine >107 umol/l 208 (23%) 86 (19%) 74 (25%) 48 (35%) 0.001
Heart rate > = 110 beats/min 85 (10%) 38 (8%) 33 (11%) 14 (10%) 0.487
Systolic blood pressure <100 mmHg 32 (4%) 13 (3%) 16 (5%) 3 (2%) 0.132
Polypharmacy 452 (51%) 225 (50%) 135 (45%) 92 (68%) <0.001
Anticoagulation prior to index VTE 44 (5%) 24 (5%) 12 (4%) 8 (6%) 0.622
Type of initial parenteral anticoagulation 0.388
  Low-molecular-weight heparin 435 (49%) 232 (51%) 140 (47%) 63 (46%)
  Unfractionated
heparin 273 (31%) 142 (31%) 93 (31%) 38 (28%)
  Fondaparinux 149 (17%) 63 (14%) 55 (18%) 31 (23%)
  Danaparoid 1 (0%) 1 (0%) 0 (0%) 0 (0%)
  None 30 (3%) 14 (3%) 12 (4%) 4 (3%)
Initial Vitamin K antagonist therapy 773 (87%) 390 (86%) 261 (87%) 122 (90%) 0.581
Concomitant antiplatelet therapy 282 (32%) 131 (29%) 90 (30%) 61 (45%) 0.002
HbA1c [%] 5.70 (5.40; 6.10) 5.40 (5.20; 5.60) 6.00 (5.90; 6.20) 7.00 (6.70; 7.60)
Table 1. Baseline characteristics by HbA1c categories. Values were missing in body mass index (1%), heart rate 
(2%), systolic blood pressure (2%), anaemia (6%), platelet count (6%) and creatinine (8%). Provoked venous 
thromboembolism was defined as presence of at least one of the following factors: major surgery, oestrogen 
therapy or immobilization during the last 3 months. Active cancer was defined as cancer that required therapie 
(surgery, chemotherapy, and/or radiotherapy) during the last 3 months. Major bleeding was defined as a fatal 
bleeding, a symptomatic bleeding in a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, 
intraarticular, pericardial, or intramuscular with compartment syndrom), a bleeding with a reduction of 
hemoglobin ≥20 g/l, or a bleeding leading to the transfusion ≥2 units of packed red blood cells. Polypharmacy 
was defined as prescription of more than four different drugs. IQ = interquartile, PE = pulmonary embolism, 
TIA = transient ischemic attack, VTE = venous thromboembolism.
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and Table 3). In a secondary analysis, we studied a possible non-linear relationship between continuous HbA1c 
values and mortality in a fractional polynomial Cox-proportional hazards model. This model showed a U-shaped 
relationship between HbA1c and relative hazards of mortality (p = 0.002, Fig. 3a). This result was confirmed when 
assuming a quadratic relationship by using a linear and quadratic term for HbA1c in a Cox-proportional hazards 
model (p = 0.02).
A total of 186 deaths were observed: 61 deaths (32.8%) were attributable to cancer, 7 (3.8%) PE related, 28 
[15.1%] possibly PE related, 16 (8.6%) to sepsis, 14 (7.5%) to infection, 12 (6.5%) to bleeding, 11 (5.9%) to left 
ventricular failure, 6 (3.2%) to pulmonary causes other than PE, 3 (1.6%) to acute coronary syndrome, 2 (1.1%) to 
stroke, 3 (1.6%) to suicide, 4 (2.2%) to others, and 19 (10.2%) to unknown causes (Supplemental Table 1).
In the subgroup analysis of patients without a history of diabetes, we observed similar results. HbA1c in dia-
betes range was significantly associated with a higher risk of mortality (aHR 2.12 [1.16–3.90] p = 0.015). The risk 
of mortality was similar between patients with pre-diabetes and patients with normal HbA1c levels (aHR 1.20 
[0.81–1.76] p = 0.366) (Table 3). Causes of death are shown in Supplemental Table 1.
In the subgroup analysis of patients with a history of diabetes, the risk of all-cause mortality was higher in 
patients with HbA1c in normal range (aHR 1.44 [0.45–4.60] p = 0.537) and HbA1c in diabetes range (aHR 1.39 
[0.53–3.65], p = 0.498), as compared to individuals with HbA1c in pre-diabetes range. Interestingly, all deaths in 
patients with known diabetes and HbA1c levels <5.7% occurred within the first year of follow up. Causes of death 
are shown in Supplemental Table 1.
In a secondary analysis, we determined relative hazards for mortality according to HbA1c values. The frac-
tional polynomial Cox-proportional hazards model showed a U-shaped relationship between continuous HbA1c 
and mortality (Fig. 3a–c).
Major bleeding. The risk of major bleeding was not greater in patients with HbA1c in pre-diabetes range 
(aSHR 0.82 [0.54–1.23] p = 0.328) and diabetes range (aSHR 0.67 [0.39–1.18] p = 0.168) compared to patients 
with HbA1c in normal range. Similar results were obtained in the subgroup analysis (data not shown).
Figure 1. Kaplan-Meier estimates of cumulative VTE recurrence by HbA1c categories. The cumulative 
incidence of recurrent VTE did not differ between groups (log-rank p = 0.766).
HbA1c group HbA1c n/N
Crude SHR 
(95%-CI) p-value
Adjusted SHR 
(95%-CI) p-value
All patients
normal range <5.7% 56/452 1 (reference) 1 (reference)
pre-diabetes range 5.7 to <6.5% 40/300 1.11 (0.74 to 1.66) 0.617 1.07 (0.70 to 1.63) 0.756
diabetes range ≥6.5% 13/136 0.75 (0.41 to 1.38) 0.353 0.73 (0.39 to 1.37) 0.328
Patients with history 
of diabetes
normal range <5.7% 3/26 0.76 (0.19 to 2.98) 0.696 0.81 (0.22 to 3.00) 0.754
pre-diabetes range 5.7 to <6.5% 6/34 1 (reference) 1 (reference)
diabetes range ≥6.5% 8/79 0.62 (0.22 to 1.75) 0.365 0.68 (0.24 to 1.92) 0.468
Patients without 
history of diabetes
normal range <5.7% 53/426 1 (reference) 1 (reference)
pre-diabetes range 5.7 to <6.5% 34/266 1.08 (0.70 to 1.66) 0.731 1.03 (0.66 to 1.62) 0.884
diabetes range ≥6.5% 5/57 0.67 (0.27 to 1.68) 0.393 0.70 (0.27 to 1.79) 0.454
Table 2. Association of HbA1c categories with VTE recurrence. VTE recurrence was adjusted for age, gender, 
active cancer, provoked VTE, prior VTE, body mass index and periods of anticoagulation as a time-varying 
covariate. CI = confidence interval, n = number of events, N = number of patients, SHR = sub-hazard ratio, 
VTE = venous thromboembolism.
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Discussion
This prospective multicenter cohort study investigated the association of HbA1c with recurrent VTE, all-cause 
mortality, and major bleeding in elderly patients with acute VTE. The prevalence of diabetes and prediabetes 
according to HbA1c levels was very high, amounting to 22.1% and 30.0%, respectively. During the follow-up, 
109 patients (12%) experienced a recurrent VTE and 186 patients died (21%). We found no association between 
HbA1c levels and recurrent VTE and patients with HbA1c in pre-diabetes or diabetes range despite a higher 
baseline unprovoked VTE proportion (prediabetes range +13%, diabetes range +10%). However, our results 
showed that an HbA1c ≥ 6.5% was significantly associated with a higher mortality risk in both patients with 
and without a history of diabetes confirming results of previous studies56,57. Most interestingly, we found a flat 
U-shaped relationship between continuous HbA1c values and mortality, as had been observed earlier, however 
in a much younger population58,59. Lastly, we found that HbA1c levels were not associated with major bleeding.
Our results regarding VTE recurrences are in contrast with recent studies, which found a positive relationship 
between diabetes and the incidence of recurrent VTE39,40. These studies may have possible bias by defining DM 
according to medical chart review and not by measuring HbA1c. One important reason for the lack of association 
between HbA1c and recurrent VTE in our study is the fact that the diabetic patients were well controlled; only 6% 
(n = 54) of participants had an HbA1c > 7.3% and only 3% (n = 26) had an HbA1c > 8%. We cannot exclude an 
association of poorly controlled diabetes exhibiting very high HbA1c levels with recurrent VTE, which should be 
motivation enough to achieve better diabetes control.
We found a U-shaped relationship between continuous HbA1c values and all-cause mortality, demonstrating 
that patients with elevated HbA1c as well as patients with low HbA1c values are at higher mortality risk. Due to 
the very low proportion of high HbA1c, i.e. >8% (n = 26) in patients with history of diabetes, our HbA1c nadir 
with the lowest mortality rate (6.7%) was lower than in another study (HbA1c nadir 7.5–7.9%)58, again suggesting 
excellent diabetes control. The HbA1c nadir was 5.5% in our patients without history of diabetes and therefore 
comparable to other articles (HbA1c nadir 5.3%)59.
Figure 2. Kaplan-Meier estimates of cumulative mortality by HbA1c categories. The cumulative mortality was 
higher in patients with HbA1c ≥ 6.5% than in patients with lower HbA1c levels (log-rank p = 0.025).
HbA1c group HbA1c n/N
Crude HR  
(95%-CI) p-value
Adjusted HR 
(95%-CI) p-value
All patients
normal range <5.7% 90/452 1 (reference) 1 (reference)
pre-diabetes range 5.7 to <6.5% 55/300 0.94 (0.67 to 1.32) 0.741 1.17 (0.82 to 1.69) 0.388
diabetes range ≥6.5% 41/136 1.57 (1.09 to 2.25) 0.015 1.83 (1.21 to 2.75) 0.004
Patients with 
history of diabetes
normal range <5.7% 8/26 2.24 (0.74 to 6.82) 0.154 1.44 (0.45 to 4.60) 0.537
pre-diabetes range 5.7 to <6.5% 6/34 1 (reference) 1 (reference)
diabetes range ≥6.5% 25/79 2.04 (0.81 to 5.14) 0.130 1.39 (0.53 to 3.65) 0.498
Patients without 
history of diabetes
normal range <5.7% 82/426 1 (reference) 1 (reference)
pre-diabetes range 5.7 to <6.5% 49/266 1.00 (0.70 to 1.43) 0.991 1.20 (0.81 to 1.76) 0.366
diabetes range ≥6.5% 16/57 1.51 (0.88 to 2.58) 0.135 2.12 (1.16 to 3.90) 0.015
Table 3. Association of HbA1c categories with mortality. Mortality was adjusted for age, gender, active cancer, 
immobilization, heart failure, chronic lung disease, overt pulmonary embolism, history of major bleeding, high 
pulse, low blood pressure, anemia, high creatinine, body mass index and periods of anticoagulation as a time-
varying covariate. HR = hazard ratio, n = number of events, N = number of patients.
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Figure 3. Relative hazards for mortality according to HbA1c values. Adjusted hazard ratios with 95% 
confidence intervals from a fractional polynomial Cox-proportional hazards model with robust standard errors. 
HbA1c values were used log-transformed and centered at the mean. Both axes are shown on a natural-log scale. 
(a) Relative hazards for mortality according to HbA1c values in all patients (N = 888). The relationship between 
continuous HbA1c and mortality is U-shaped (p = 0.002). The plot was truncated at the 2.5th and 97.5th 
percentile of HbA1c (4.7% and 8.3%, respectively). (b) Relative hazards for mortality according to HbA1c 
values in subgroup of patients with history of diabetes (N = 139). The relationship between continuous HbA1c 
and mortality is slightly U-shaped (p = 0.63) in patients with history of diabetes. The plot was truncated at the 
5th and 95th percentile of HbA1c (5.2% and 9.8%, respectively). (c) Relative hazards for mortality according 
to HbA1c values in subgroup of patients without history of diabetes (N = 749). The relationship between 
continuous HbA1c and mortality is U-shaped (p = 0.064). The plot was truncated at the 2.5th and 97.5th 
percentile of HbA1c (4.7% and 6.9%, respectively).
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In the subgroup of patients with a history of diabetes, HbA1c in diabetes range and HbA1c in normal range 
were positively associated with higher mortality rates taking the HbA1c category pre-diabetes range as the ref-
erence. The higher mortality in the HbA1c < 5.7% group corresponds to the observation of others60. A possible 
explanation is an association of lower HbA1c values with severe illness or (overly) tight glycemic control with 
recurrent hypoglycemias. Hypoglycemia decreases myocardial perfusion61 and leads to prolonged QT in patients 
with diabetes type 162. Such findings may explain the association (and pathophysiology) of hypoglycemia and 
increased cardiovascular mortality including sudden deaths in susceptible individuals.
The prevalence of diabetes (22.1%) and prediabetes (30.0%) was remarkably high in this elderly popula-
tion with acute VTE and slightly higher compared to the percentages found in the CoLaus study, a population 
based study from Lausanne, Switzerland63. In the CoLaus study the prevalence of type 2 DM (defined as fasting 
plasma glucose >7 mmol/l and/or antidiabetic treatment) in the age group 65–75 years was 18.9%. In the KORA 
Augsburg study, a population based study in the southern part of Germany64, prevalence of DM was 22.4% in the 
age group 65–74 years and therefore comparable to our observation. Even higher diabetes prevalence was found 
in the US with 26% in the general population aged 65 years and older65.
The CoLaus study found that roughly one third were newly diagnosed diabetics after determination of 
increased plasma glucose levels. Likewise, we found that 29.1% of diabetic patients were newly diagnosed after 
HbA1c determination in our study population.
Our study has several limitations. The number of primary endpoint events in the subgroup of patients with 
history of diabetes was relatively low. HbA1c values have been measured at baseline and may have changed over 
the years of follow-up. Information on additional biological factors which may have influenced HbA1c levels66, 
such as conditions with rapid red cell turnover (hemoglobinopathies or transfusion) are lacking, albeit in most 
instances unlikely to be present. Likewise, we had no information on therapy and duration of DM. Known diabe-
tes was defined by patient reports in addition to medical records; therefore, we cannot exclude that some patients 
have falsely been allocated to the group of “patients without a history of diabetes”. Furthermore, HbA1c level is 
age dependent. Despite similar blood glucose levels, HbA1c levels in participants aged >70 years were approx-
imately 0.4 percentage point higher than in those <40 years of age in the Framingham study67. Nevertheless, 
to date, no age-specific diagnostic criteria or adaptations of any normal HbA1c values exist. The current study 
focuses exclusively on high risk patients above 65 years of age with acute VTE and therefore the data cannot be 
extrapolated to the general population. Despite extensive adjustments, we cannot exclude residual confounding. 
And finally, due to the relatively low number of elevated HbA1c values above 8%, our study does not exclude a 
potential association of poorly controlled diabetes with recurrent VTE.
In summary, we found that diabetes does not appear be an independent predictor for recurrent VTE in elderly 
patients with VTE. Likewise, HbA1c levels were not associated with major bleedings. However, we found a 
U-shaped relationship of HbA1c levels with all-cause mortality in elderly patients with acute VTE with the lowest 
mortality rate at an HbA1c level of 6.7% for patients with history of diabetes and 5.5% for patients without history 
of diabetes.
Data availability
The datasets used and/or analyzed during the current study are available from the corresponding author upon 
reasonable request.
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